Oligodendroglioma (OG) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Oligodendroglioma (OG) Market Outlook

Thelansis’s “Oligodendroglioma (OG) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oligodendroglioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Oligodendroglioma Overview

Oligodendroglioma (OG) is a rare type of glial tumor primarily found in the white matter of the cerebral hemisphere, especially in the supratentorial region. This tumor is characterized by a highly cellular lesion that diffusely infiltrates the periphery and consists of evenly-spaced monomorphic cells with the oligodendroglial phenotype. The cells are uniformly round to oval with round nuclei, delicate chromatin and small nucleoli. The most common clinical presentation is seizures. There are three types of OG: Grade 2 oligodendroglioma (low grade), Grade 2 oligoastrocytoma (low grade), Grade 3 anaplastic oligodendroglioma (high grade), and Grade 3 anaplastic oligoastrocytoma (high grade). The cause of OG is still unknown, but certain risk factors such as age, exposure to ionizing radiation, and family history of glioma can increase the risk of developing this tumor. Treatment of OG is multifactorial and includes surgical, chemotherapy, and radiation therapy methods. Low-grade OG (WHO Grade II), which has 1p/19q deletion and IDHmt, have a better prognosis than other astrocytomas without these genetic markers. OGs have a median survival time of 10-12 years and 5- years progression-free and overall survival rates of 51-83%. Overall and 5-year survival rates decrease with higher-grade anaplastic OG, with a median survival time of 3.5 years in WHO Grade III tumors. Diffuse astrocytoma is the primary differential diagnosis on imaging and is difficult to distinguish from OG. Complications from OGs may include seizures, postsurgical complications, thromboembolic events, chemotherapy side effects, and long-term effects of radiation, such as cognitive deficits, gait abnormalities, or radiation necrosis. Residual or recurrent OGs can also undergo malignant degeneration over time.

• Oligodendrogliomas are estimated to account for 1.3% of brain tumors in the United States, with approximately 1,100 new diagnoses each year.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: